MAZE - CIK 0001842295
The table below shows Maze Therapeutics, Inc.'s cash flow statement line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating cash flow | -$111.94M | $75.95M |
| Capital expenditure | $794.00K | $1.15M |
| Investing cash flow | -$170.96M | -$1.15M |
| Dividends paid | - | - |
| Stock buybacks | - | - |
| Financing cash flow | $275.34M | $92.85M |
Maze Therapeutics, Inc. reported operating cash flow of -$111.94M for fiscal year 2025. That is down 247.4% from $75.95M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.